He looked at insurance claims data in a research letter published in JAMA and found that few patients actually adhere to the drugs for the long term
In August 2025, Eli Lilly announced that its experimental oral GLP-1 orforglipron achieved better weight loss and blood sugar control than oral semaglutide in a head-to-head late-stage trial
Early community reports suggest combined visceral fat losses of 20 to 30% alongside total weight reductions of 25 to 30% over a six-month period, though these numbers remain anecdotal
This benefit extends to the sublingual form, making it a valuable medication for protecting heart health in people with type 2 diabetes
The enforcement mechanism is reactive, not proactive
In a major clinical trial, participants on semaglutide plus lifestyle changes lost about 15 % of their body weight on average, while those on placebo lost around 2 %public-health.uq.edu.au